A newer hyperthermic therapy with a bacterial immunopotentiator (OK432) for chemotherapy-resistant ovarian cancer.
Systemic hyperthermic therapy was applied to two patients with chemotherapy-resistant malignancy. To obtain hyperthermia, a pyretic effect of a bacterial immunostimulant (OK432) was utilized. In a case of pseudomyxoma peritonei, her distended abdominal girth showed a remarkable decrease during this therapy. In another case, an endodermal sinus tumor, the serum alpha fetoprotein (AFP) level of the patient was lowered temporally and leukopenia induced by prior cytotoxic chemotherapies was significantly recovered. Because of the anticancer effect of OK432 itself, an accurate evaluation of this is difficult. At a moderate estimate, however, this method seems to be feasible as a useful adjuvant therapy in the management of cancer.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use*; D001831:Body Temperature; D002272:Carcinoembryonic Antigen / Q000032:analysis; D004351:Drug Resistance; D005260:Female; D006358:Hot Temperature / Q000627:therapeutic use*; D006801:Humans; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D010844:Picibanil / Q000627:therapeutic use*; D000509:alpha-Fetoproteins / Q000032:analysis
D001688:Biological Products; D002272:Carcinoembryonic Antigen; D000509:alpha-Fetoproteins; D010844:Picibanil